• Explore /
  • Poster
  • / Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).

Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

null

Shen Zhao

Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

Shen Zhao , Hongyun Zhao , Li Zhang , Yuping Sun , Wu Zhuang , Xiaorong Dong , Jianying Zhou , Mingjun Li , Xiaoyan Li , yuqin xi , Jintao Zhang , Wen Xu , Ao Li , Qianrong Chen , Linda J. Paradiso , Thomas J. Myers , Lei Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT05489731

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 8077)

DOI

10.1200/JCO.2024.42.16_suppl.8077

Abstract #

8077

Poster Bd #

339

Abstract Disclosures

Similar Posters

First Author: Jonathan N. Priantti

First Author: Collin M. Blakely

First Author: Jonathan W. Riess

First Author: Jonathan W. Goldman